86 Results for "

RIPK1 Inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (86)

86 Results for "RIPK1 Inhibitor" in MCE Product Catalog:

34
34 Publications Verification
Cat. No.: HY-14622A
CAS No.: 852391-15-2
Purity:  99.65%
Synonyms: Necrostatin 1S; Nec-1S; 7-Cl-O-Nec1
Target:  

RIP kinase

Research Areas:  

Cancer

Necrostatin 2 racemate (Nec-1S), the Necrostatin-1 (HY-15760) stable, is a potent and specific RIPK1 inhibitor lacking the IDO-targeting effect .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-14622
CAS No.: 852391-19-6
Purity:  99.92%
Target:  

RIP kinase

Research Areas:  

Cancer

Necrostatin 2 is a potent necroptosis inhibitor. EC50 for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF-α is 0.05 μM. Necrostatin 2 is also a RIPK1 inhibitor.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N1535
CAS No.: 52617-37-5
Synonyms: Rubescensine B
Ponicidin (Rubescensine B) is an orally active RIPK1 inhibitor with a Kd value of 135 nM. Ponicidin inhibits the JAK2/STAT3 pathway to induce apoptosis, activates the PI3K/Akt pathway, upregulates SIRT1 expression, alleviates oxidative stress, suppresses inflammatory responses and necroptosis, and blocks cell cycle progression. Ponicidin induces ROS production to exert antiproliferative and antiviral effects, while also improving cognitive function and reducing plaque deposition. Ponicidin can be used in studies related to hepatocellular carcinoma, Alzheimer's disease, and gastric cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0546
CAS No.: 260413-62-5
Synonyms: Nuezhenoside
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-134050
CAS No.: 2559703-06-7
Purity:  99.84%
Synonyms: Apt-1
Apostatin-1 (Apt-1) is a potent TRADD inhibitor. Apostatin-1 can bind with TRADD-N (KD=2.17 μM), disrupting its binding to both TRADD-C and TRAF2. Apostatin-1 modulates the ubiquitination of RIPK1 and beclin 1. Apostatin-1 blocks apoptosis and restores cellular homeostasis by activating autophagy in cells with accumulated mutant tau, α-synuclein, or huntingtin .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-138779
CAS No.: 1803605-68-6
Purity:  99.25%
Research Areas:  

Inflammation/Immunology

ICCB-19 hydrochloride is a TRADD (TNFRSF1A associated via death domain) inhibitor. ICCB-19 hydrochloride binds with N-terminal domain of TRADD (TRADD-N), disrupting its binding to both TRADD-C and TRAF2. ICCB-19 hydrochloride is indirect inhibitor of RIPK1 kinase activity. ICCB-19 hydrochloride effectively induces autophagy and the degradation of long-lived proteins .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-131064
CAS No.: 2361139-70-8
Purity:  99.19%
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC50 of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC50s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC50 of 1.1 μM .
loading...
    loading...
Cat. No.: HY-114371
CAS No.: 2125450-76-0
Purity:  99.77%
Synonyms: DNL-758; SAR-443122
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

Eclitasertib (DNL-758) is a potent receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC50 of 0.0375 µΜ .
loading...
    loading...
Cat. No.: HY-114492
CAS No.: 2226735-55-1
Purity:  99.92%
Synonyms: GSK'547
Target:  

RIP kinase

Research Areas:  

Cancer

GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer .
loading...
    loading...
Cat. No.: HY-148297
CAS No.: 2382811-41-6
Purity:  98.75%
Synonyms: LY3871801; R 552
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

Ocadusertib is a potent Serine/Threonine kinase receptor-interacting protein kinase 1 (RIPK1) inhibitor .
loading...
    loading...
Cat. No.: HY-128348
CAS No.: 2173556-69-7
Purity:  99.92%
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology Cancer

PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC50 of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis .
loading...
    loading...
Cat. No.: HY-N0660
CAS No.: 55466-05-2
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .
loading...
    loading...
Cat. No.: HY-119933
CAS No.: 2300982-44-7
Purity:  98.56%
Target:  

RIP kinase

Research Areas:  

Cancer

RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model .
loading...
    loading...
Cat. No.: HY-132203
CAS No.: 375835-43-1
Purity:  98.90%
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology Cancer

Necrostatin-34 (Nec-34), a RIPK1 kinase inhibitor, stabilizes RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain .
loading...
    loading...
Cat. No.: HY-148787
CAS No.: 2252271-93-3
Purity:  99.24%
Synonyms: SAR443820; DNL788
Target:  

RIP kinase

Oditrasertib (SAR443820) is an orally active, BBB-penetrable and selective reversible inhibitor of RIPK1. Oditrasertib can be used in the research of chronic inflammatory central nervous system diseases, such as amyotrophic lateral sclerosis and multiple sclerosis .
loading...
    loading...
Cat. No.: HY-120548
CAS No.: 1143863-69-7
Purity:  99.52%
Research Areas:  

Cancer

KBU2046 is an orally active transforming growth factor-β (TGF-β1) inhibitor. KBU2046 reduces integrin family protein expression, decreases Raf, RIPK1 and ERK phosphorylation to deactivate the ERK signaling pathway, and down-regulates genes linked to TGF-β1 maturation. KBU2046 suppresses tumor cell motility, impedes cancer invasion and metastasis, and inhibits human ESCC growth and metastasis in a murine model. KBU2046 can be used for the researches of triple-negative breast cancer and esophageal squamous cell carcinoma .
loading...
    loading...
Cat. No.: HY-18901
CAS No.: 1481641-08-0
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

RIPK1-IN-4 (compound 8) is a potent and selective type II kinase inhibitor of receptor interacting protein 1 (RIP1) kinase and binds to a DLG-out inactive form of RIP1 with an IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase .
loading...
    loading...
Cat. No.: HY-108636
CAS No.: 1036069-26-7
Purity:  99.42%
RETRA is a RIPK1/RIPK3/MLKL and p73 activator. RETRA mediates plasma membrane disruption, induces ROS accumulation, triggers early mitochondrial hyperpolarization, and synergistically drives necroptosis. RETRA inhibits cancer cells carrying mutant p53 via a p73-dependent salvage pathway. RETRA can be used in research related to cervical cancer and cancers with mutant p53 .
loading...
    loading...
Cat. No.: HY-151369
CAS No.: 233605-81-7
Purity:  99.60%
AV123 (compound 12) is a non-cytotoxic RIPK1 inhibitor (IC50=12.12 µM). AV123 blocks the TNF-α-induced necroptotic (EC50=1.7 μM) but not the apoptotic cell death. AV123 can be used in the study of necrotic chronic conditions such as ischemia-reperfusion injury of the brain, heart and kidney, inflammatory diseases, neurodegenerative diseases and infectious diseases .
loading...
    loading...
Cat. No.: HY-157456
CAS No.: 2763831-43-0
Purity:  ≥98.0%
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

RIPK1-IN-19 is a selective RIPK1 inhibitor (IC50=15 nM). RIPK1-IN-19 does not show obvious activity against RIPK2, RIPK3, and RIPK4. RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ)-induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases .
loading...
    loading...